Form 4: Catheter Precision, Inc. Executive Jacques Marie-Claude Reports Stock Option Grant
SEC Form 4 Filing
Chief Commercial Officer Jacques Marie-Claude reports the acquisition of stock options in Catheter Precision, Inc.
Summary
- On May 3, 2024, Jacques Marie-Claude, Chief Commercial Officer of Catheter Precision, Inc., filed a Form 4.
- The report details the acquisition of options to purchase 250,000 shares of common stock at an exercise price of $0.5321 on May 1, 2024.
- These options vest annually over five years and expire on May 1, 2034.
- The reporting person also disposed of 250,000 options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock option grants.
Positives
- The grant of stock options to a key executive aligns their interests with those of the shareholders.
Industry Context
Stock option grants are a common practice in the industry to incentivize and retain key executives.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of transaction: Jacques Marie-Claude acquired options to purchase 250,000 shares of common stock and disposed of 250,000 options. |
| 05/03/2024 | Date of Form 4 filing. |
| 05/01/2034 | Expiration date of the options. |
Keywords
Form 4, stock options, insider trading, Jacques Marie-Claude, Catheter Precision, Inc., VTAK, Chief Commercial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.